Skip to main content
Evidence Snapshot

Dihydrofolate reductase

CHEMBL202 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:47Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL202
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Dihydrofolate reductase as ChEMBL target CHEMBL202, mapped to UniProt P00374. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Dihydrofolate reductase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL202
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00374
Dihydrofolate reductase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Dihydrofolate reductase matters

As of 2026-09-13

Dihydrofolate reductase is reviewed as Dihydrofolate reductase (UniProt P00374); Dihydrofolate reductase shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 18 approved drugs, 2072 compounds, and 453 assays, with lead potency reaching pChEMBL 11.0.

Disease context
non-small cell lung carcinoma

Dihydrofolate reductase shows approved-linked disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include METHOTREXATE, PEMETREXED, PEMETREXED DISODIUM.

Start review with non-small cell lung carcinoma because it currently carries approved-linked support. Linked drugs include METHOTREXATE, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 18 approved drugs, 2072 compounds, and 453 assays for this target. The dominant activity type is IC50. CHEMBL305177 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL305177 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
18 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Dihydrofolate reductase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00374, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why non-small cell lung carcinoma is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2072
Total Compounds
453
Total Assays
18
Approved Drugs
IC50: 1546.0, KI: 512.0, KD: 86.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL305177
 11.0 Ki —
No preferred name
CHEMBL34259
 11.0 Ki Approved
No preferred name
CHEMBL1201746
 10.9 Ki Approved
No preferred name
CHEMBL7492
 10.6 Ki Clinical
No preferred name
CHEMBL390990
 10.5 Ki —

Approved Drugs

Structure Compound First Approval
TERIFLUNOMIDE
CHEMBL973
 2012
PRALATREXATE
CHEMBL1201746
 2009
PEMETREXED
CHEMBL225072
 2004
RALTITREXED
CHEMBL225071
 1996
TRIMETREXATE
CHEMBL119
 1993
TRIMETHOPRIM
CHEMBL22
 1973
METHOTREXATE
CHEMBL34259
 1953
PYRIMETHAMINE
CHEMBL36
 1953
SULFADIAZINE
CHEMBL439
 1941
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:50:47Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL202